Join
Live feed
·
PRReleasevia Quantisnow
Lisata Therapeutics Inc. logo

Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly

ByQuantisnow·Wall Street's wire, on your screen.
LSTA· Lisata Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track LSTA (Lisata Therapeutics Inc.) and more on Quantisnow.